Lilly Alimta Favorable Toxicity Outweighs Uncertain Survival Effect, Cmte Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s oncologic drugs advisory committee recommends accelerated approval of Alimta for the treatment of second line non-small cell lung cancer. Alimta results in less neutropenia and other adverse events, committee says.
You may also be interested in...
Lilly's Alimta Approved For Lung Cancer; "Reasonably Likely" To Improve Survival
While no controlled trials demonstrated a clinical benefit of pemetrexed in non-small cell lung cancer, a surrogate endpoint of patient response rate suggests a survival benefit.
Lilly's Alimta Approved For Lung Cancer; "Reasonably Likely" To Improve Survival
While no controlled trials demonstrated a clinical benefit of pemetrexed in non-small cell lung cancer, a surrogate endpoint of patient response rate suggests a survival benefit.
Taxotere Would Be Unaffected By Alimta Approval, Aventis Says
Aventis expects Taxotere growth to remain unchanged should FDA approve Lilly's thymidylate synthase inhibitor Alimta for the treatment of second line non-small cell lung cancer